Karolinska Development has the pleasure of inviting professional investors, financial analysts and media to attend the company’s Capital Markets Day on Tuesday October 21, 2014 between 09h00-12h00 at Karolinska Development’s premises in Solna, Sweden.
On account of the Capital Markets Day, Karolinska Development has decided to present its interim report for the third quarter 2014 that same day. i.e. on October 21, 2014.
The purpose of the Capital Markets Day is to present Karolinska Development’s new strategy, some of the portfolio companies, the third quarter report as well as to introduce the acting CEO Klaus Wilgenbus.
The Chairman of the Board, Bo Jesper Hansen, will host the meeting. Presentations will also be made by the acting CEO Klaus Wilgenbus as well as the CEO’s of some of the portfolio companies.
Please register at cmd@karolinskadevelopment.com before October 14, 2014. Additional details will be posted on the company’s website in due course.
For more information, please contact:
Klaus Wilgenbus, Acting CEO Karolinska Development, Phone + 46 72 245 9892
TO THE EDITORS
About Karolinska Development AB
Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into differentiated products that can be partnered. The business model is to: SELECT the most commercially attractive medical innovations that can potentially satisfy unmet medical needs; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading universities, delivers a continuous flow of innovations. Today, the portfolio consists of 33 projects, of which 16 are in clinical development. For more information, please visit www.karolinskadevelopment.com.
Karolinska Development is listed on NASDAQ OMX. Karolinska Development may be required to disclose the information provided herein pursuant to the Securities Markets Act.
